Clinical Trial Update: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy [Phase 1]

View source ↗

Summary

This document provides a status update for a Phase 1 clinical trial evaluating the SVN53-67/M57-KLH peptide vaccine in newly diagnosed multiple myeloma patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• SVN53-67/M57-KLH peptide vaccine (SVN53-67/M57-KLH peptide vaccine)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING